Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26425312 | 0.88 | NFE2L2 (0.41) | PDE4BPDE4APDE4CPDE4DNFE2L2 | |
| SCHEMBL26425553 | 0.85 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL26425307 | 0.85 | NFE2L2 (0.52) | NFE2L2 | |
| SCHEMBL26425326 | 0.81 | NFE2L2 (0.50) | NFE2L2CA1CA2PDE3APTGS1 | |
| SCHEMBL26425533 | 0.77 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL26425317 | 0.76 | APP (0.38) | PDE4BNFE2L2 | |
| SCHEMBL26425332 | 0.75 | AHR (0.43) | PDE4BPDE4APDE4CPDE4DCA1 | |
| SCHEMBL26425331 | 0.74 | RELA (0.40) | PDE4BPDE4APDE4CPDE4DNFE2L2 | |
| SCHEMBL26425319 | 0.74 | PDE4A (0.41) | PDE4BPDE4APDE4CPDE4DNFE2L2 | |
| SCHEMBL26425309 | 0.72 | CHAT (0.42) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | THE GEORGE WASHINGTON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129381-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANTICANCER-DRUG RESISTANT CANCERS | TP53, ANXA5, MCL1 | PDE4B 2973/4885PDE4A 3402/4885PDE4C 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.